Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | PHASE1 | COMPLETED | 54 | — | — | Jul 1, 2004 | Feb 1, 2006 | Jan 29, 2009 | 19 | United States, Israel |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Idarubicin plus amifostine |
| 2 | EXPERIMENTAL | Idarubincin |
| Name | Type | Description |
|---|---|---|
| Idarubincin and Amufostine (Ethyol) | DRUG | Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36) |
| Idarubincin | DRUG | Idarubincin (12mg/m2) and ara-C(N-18) |
Inclusion Criteria: * Adult men and women of at least 60 years of age at the time of entry or randomization; * Histologically proven AML with at least 20% myeloblasts based on bone marrow aspiration and biopsy performed within 5 days prior to entry or randomization; History of prior MDS allowed pro...